MedStar, PathAI expand network
MedStar Health and PathAI are expanding a digital‑pathology network that combines an AI‑enabled platform with MedStar’s labs and more than 40 pathologists to improve workflow efficiency and future diagnostic AI deployments. The project shows AI gaining traction first in specialised, image‑rich domains where infrastructure can be standardised. (digitalhealthnews.com)
Pathology is the part of medicine where doctors study tiny slices of tissue under a microscope to decide whether a lump is harmless, inflamed, or cancerous. For more than a century, that work usually meant a glass slide, a light box, and one specialist looking through one lens at a time. (360dx.com) Digital pathology turns that glass slide into a giant image file that can be zoomed, shared, and stored like a map on a screen. Once the tissue is scanned, a pathologist can review it remotely instead of waiting for a physical slide to move from one lab bench to another. (pathai.com) That digital step is what makes artificial intelligence useful here. A computer can only help if the tissue image is already in a standard digital format, the same way spellcheck only works after a page has been typed into a computer. (pathai.com) Now MedStar Health is expanding that setup across its lab network with PathAI’s AISight Dx platform in a multi-year deal announced on April 7, 2026. MedStar said the system will support more than 40 pathologists across its multi-site health system in the Washington area. (pathai.com) AISight Dx is the software layer that stores slide images, lets doctors view them, and plugs in image-analysis tools on top. PathAI says the platform is cloud-native, which means the files and workflow are built to be shared across locations instead of trapped on one hospital server. (pathai.com) This is not just a pilot for research slides. PathAI said on June 30, 2025 that the United States Food and Drug Administration cleared AISight Dx for primary diagnosis in clinical settings, which is the formal step that lets a system be used in routine patient care rather than only in back-office experiments. (pathai.com) MedStar is also buying algorithms, not just a viewer. PathAI said the health system plans to deploy tools including PathExplore Fibrosis, which is designed to measure fibrosis on liver biopsy images, giving pathologists a quantified readout instead of only a visual estimate. (pathai.com) The immediate sell is speed and consistency, not a robot replacing doctors. MedStar’s pathology leadership said digital pathology is central to scaling care across a large health system and a growing outreach business, which means more cases can be routed, reviewed, and discussed without shipping fragile glass between sites. (clpmag.com) The longer game is data. PathAI said the partnership connects MedStar to its Precision Pathology Network, which is aimed at joint research, real-world multimodal datasets, clinical trials, biopharma work, and co-development of future diagnostic tools. (tmcnet.com) That helps explain why pathology is one of the first hospital specialties where artificial intelligence is gaining real traction. Tissue slides are image-heavy, the questions are narrow, and the workflow can be standardized in a way that is much harder in messier parts of medicine like emergency care or primary care visits. (digitalhealthnews.com) PathAI is also scaling this model beyond one health system. Labcorp said in March 2026 that it was expanding its own collaboration with PathAI to deploy the same Food and Drug Administration-cleared platform across its network, which suggests digital pathology is moving from isolated hospital projects toward larger shared infrastructure. (labcorp.com)
